Growth of HIV-Exposed Uninfected Infants in the First 6 Months of Life in South Africa: The IeDEA-SA Collaboration. by Morden, Erna et al.
RESEARCH ARTICLE
Growth of HIV-Exposed Uninfected Infants in
the First 6 Months of Life in South Africa: The
IeDEA-SA Collaboration
Erna Morden1*, Karl-Günter Technau2, Janet Giddy3, Nicola Maxwell1, Olivia Keiser4,
Mary-Ann Davies1
1 School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa,
2 Rahima Moosa Mother and Child Hospital and University of theWitwatersrand, Johannesburg, South
Africa, 3 McCord Hospital, Durban, South Africa, 4 Institute of Social and Preventive Medicine, University of
Bern, Bern, Switzerland
* erna.morden@alumni.uct.ac.za
Abstract
Background
HIV-exposed uninfected (HEU) infants are a growing population in sub-Saharan Africa
especially with the increasing coverage of more effective prevention of mother-to-child
transmission (PMTCT) antiretroviral therapy regimens. This study describes the character-
istics of South African HEU infants, investigates factors impacting birth weight and
assesses their growth within the first 28 weeks of life.
Methods
This is a retrospective cohort based on routine clinical data from two South African PMTCT
programmes. Data were collected between 2007 and 2013. Linear regression assessed
factors affecting birth weight-for-age z-scores (WAZ) while growth (longitudinal WAZ) was
assessed using mixed effects models.
Results
We assessed the growth of 2621 HEU infants (median birth WAZ was -0.65 (IQR -1.46; 0.0)
and 51% were male). The feeding modalities practised were as follows: 0.5% exclusive
breastfeeding, 7.9% breastfeeding with unknown exclusivity, 0.08%mixed breastfeeding
and 89.2% formula feeding. Mothers with CD4 <200 cells/μl delivered infants with a lower
birth WAZ (adjusted ß -0.253 [95% CI -0.043; -0.072], p = 0.006) compared to mothers with
aCD4500 cells/μl. Similarly, mothers who did not receive antiretroviral drugs delivered
infants with a lower birth WAZ (adjusted ß -0.39 [95% CI -0.67; -0.11], p = 0.007) compared
to mothers who received antenatal antiretrovirals. Infants with a birth weight <2 500g (ß
0.070 [95% CI 0.061; 0.078], p <0.0001) experienced faster growth within the first 28 weeks
of life compared to infants with a birth weight2 500g. Infants with any breastfeeding expo-
sure experienced slower longitudinal growth compared to formula fed infants (adjusted ß
-0.012 [95% CI 0.021; -0.003], p = 0.011).
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Conclusion
Less severe maternal disease and the use of antiretrovirals positively impacts birth weight
in this cohort of South African HEU infants. Formula feeding was common with breastfed
infants experiencing marginally slower longitudinal growth.
Introduction
HIV-exposed uninfected (HEU) infants are a growing population in sub-Saharan Africa, par-
ticularly with increasing coverage of more effective prevention of mother-to-child transmission
(PMTCT) regimens such as option B/B+, antiretroviral therapy (ART) for all pregnant and
breastfeeding women either until cessation of breastfeeding or lifelong [1]. In 2010, an evalua-
tion of the South African PMTCT programme, where antenatal HIV prevalence was 32%,
found the overall early HIV transmission rate (4–8 weeks postpartum) to be 3.5% [2]—indicat-
ing a large number of exposed but uninfected infants. More recently, antenatal HIV prevalence
is 29.5% in South Africa and both effectiveness and coverage of PMTCT have improved [3].
Breastfeeding is known to transmit HIV, however its importance for infant nutritional sta-
tus, growth [4–8] and protection against morbidity [9] and mortality [10–13] is also well docu-
mented. In South Africa particularly, mixed feeding, defined by the World Health
Organization (WHO) as a combination of breast milk and/or infant formula, other liquids and
solids [14,15], is common. In an evaluation of the South African PMTCT programme, 53% of
HIV-infected mothers breastfed their infants, of whom 42% practised exclusive breastfeeding
(EBF) at 3 weeks of age. By 12 weeks of age, however, only 18% of HIV-infected mothers who
breastfed their infants were practising EBF. Among HIV-infected mothers who practised
mixed breastfeeding (MBF) at 12 weeks of age, 48% and 52% of infants were partially (breast
milk and non-nutritive and nutritive solids and liquids) and predominantly (breast milk and
non-nutritive liquids) breastfed respectively [14]. Similarly, Coutsoudis et al found 57% of
infants were mixed fed in a study conducted early in the HIV/AIDS pandemic, prior to the
PMTCT programme [9], thus mixed feeding is widely practised in South Africa.
There have been conflicting findings with respect to the effect of feeding on growth. McGrath
et al found no differences in the rate of growth between ever breastfed and formula fed infants,
withWAZ increasing in both groups during the first 6 months after which they declined [8].
However, Malawian studies found that not breastfeeding was associated with both an increased
risk of being underweight (WAZ<-2) as well as having lower weight-, length- and weight-for-
length z-scores compared to infants who were breastfed [6,7]. The Zambia Exclusive Breastfeeding
Study found that among all HEU infants there was a decline inWAZ between 4.5 and 15 months,
but that in infants who had continued breastfeeding at 4 months, the decline was lessened [16].
The early introduction of cow’s milk ( 6 weeks of age) was also found to have a negative impact
on growth [17]. The effect of feeding modality on growth may in part be context-dependent, and
affected by the extent to which the affordable, feasible, accessible, safe and sustainable (AFASS)
criteria for replacement feeding are met [14]. Longitudinal growth is not only affected by feeding
but by birth weight and maternal factors too. Infants with a higher birth weight have greater post-
natal weight-for-age (WAZ) over time compared to low birth weight (LBW) infants (<2 500g)
although postnatal growth rate in the first year of life is faster in LBW infants [4,5,8,16,17]. There
have been conflicting findings with respect to the effect of feeding on growth. Maternal health also
impacts child growth: infants of mothers with advanced disease (high viral load,100 000 copies/
ml, or low CD4 cell count,350 cells/μl) were found to have slower growth [5,16,17].
Many previous studies of growth in HEU were conducted outside South Africa, where
breastfeeding practices and access to replacement feeding may be different, and prior to
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widespread availability of effective PMTCT regimens. The aim of this analysis was therefore to
assess birth weight and growth within the first 6 months of life in HEU infants from two
PMTCT cohorts in South Africa and examine the impact of maternal factors, including disease
severity and the use of antiretrovirals, and feeding modality.
Methods
Study design, setting and participants
This was a retrospective cohort study based on routine data provided to the International Epide-
miologic Databases to Evaluate AIDS, Southern Africa (IeDEA-SA, www.iedea-sa.org) collabora-
tion. The IeDEA-SA cohort has been previously described [18,19], although this is the first
analysis of HEU infants. Two South African sites were included in this analysis namely McCord
Hospital (MH) in KwaZulu-Natal Province and RahimaMoosa Mother and Child Hospital
(RMMCH), Gauteng Province. MH was a public-not-for-profit programme where a small patient
co-payment was required at each visit, while RMMCH is a public hospital where care is provided
at no cost to pregnant women and children6 years old. Both facilities provided primary and
secondary care. We included infants born from 2007–2013. Growth monitoring and promotion
was provided based on standard practices at each facility. In South Africa, 2008 guidelines on
infant feeding advocated HIV-infected mothers exclusively breastfeed their infants unless
replacement feeding met the AFASS criteria, in which case free infant formula was provided for 6
months [20,21]. The 2010 PMTCT guidelines recommended the following antiretroviral regi-
mens: women were eligible for lifelong ART (tenofovir (TDF) + lamivudine/emtricitabine (FTC)
+ nevirapine (NVP)) if they had a CD4350 cells/μl or WHO clinical stage 3/4. Women not eli-
gible for ART (CD4>350 cells/μl or WHO clinical stage 1/2) received zidovudine (ZDV) from
14 week gestation followed by single dose NVP and ZDV during labour and TDF + FTC after
delivery [22]. Prior to 2010, women at RMMCH received single dose nevirapine (sdNVP) at
delivery only, while at MH ZDV from 14 weeks gestation plus sdNVP at delivery was used in
women ineligible for triple ART (CD4200 cells/μl). In 2011, the Tshwane declaration of sup-
port for breastfeeding was signed, ending the provision of infant formula for PMTCT in state
facilities, like RMMCH [23]. MH continued the provision of infant formulae.
We included HIV-exposed uninfected infants with at least birth weight and one subsequent
weight measurement within the first 28 weeks of life. The following maternal information was
included for the mother-infant pair: age, parity, antenatal CD4 count and antenatal anteretro-
viral use. We excluded infants diagnosed as HIV-infected (n = 126), most were diagnosed
(97%) before 3 months of age (8.7% diagnosed by 1 month, 89% between 1–3 months, 1.6%
between 3–6 months and 0.8% after 12 months of age).
Ethics statement
The IeDEA Southern Africa Collaboration has been approved by both the University of Cape
Town and University of Bern Human Research Ethics Committees. Rahima Moosa Mother
and Child Hospital and McCord Hospital have local institutional ethics approval to contribute
data to the IeDEA-SA analyses from the University of Witwatersrand and University of Cape
Town, respectively. Participating sites obtained informed consent from all subjects. The data
were anonymised and de-identified prior to analyses.
Outcomes
The primary outcome was postnatal growth within the first 28 weeks of life which was assessed
using WAZ only. We did not assess growth using length-for-age or weight-for-length as length
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measurements were not available on all infants at all time points. Factors influencing birth
weight were also assessed as birth weight impacts longitudinal postnatal growth.
When assessing postnatal growth, birth weight was considered the baseline and follow-up
visits with recorded weights were used to assess growth. WAZ was calculated using the WHO
Child growth standards (igrowup, version 3.2.2 2011) package for Stata1. All statistical analy-
ses were done using Stata1 (StataCorp. 2011. Stata Statistical Software: Release 12. College Sta-
tion, TX: StataCorp LP).
Variables
We collected data on the following maternal factors: parity (number of previous live births) for
the index pregnancy (categorised as 0, 1 and2); maternal age [<18 years (younger), 18–35
years and>35 years (older)]; antenatal CD4 cell count (<200, 200–500 and500 cells/μl) and
maternal antiretrovirals grouped into any antiretrovirals (comprising unknown regimen, nevi-
rapine (NVP) only, dual therapy and triple therapy), no antiretrovirals and missing antiretrovi-
ral information. Where maternal antiretroviral regimen was changed during the pregnancy, we
included the antenatal regimen closest to the delivery date.
Infant variables collected included the following: sex, gestational age (based on palpation or
date of last menstrual period) at delivery (term ( 37 weeks), preterm and unknown gesta-
tional age), birth weight (low (<2 500g) or normal (2 500g). Infant feeding, as it occurred
over 28 weeks, was categorised into formula feeding (FF i.e. never breastfed), unknown feeding
and any breastfeeding (BF). Any BF comprised EBF, BF with unknown exclusivity and MBF.
Analysis
Baseline characteristics between sites were compared using Wilcoxon rank-sum test for contin-
uous variables and Chi-squared or Fisher’s exact tests for categorical variables.
We first assessed factors affecting birth weight using univariate and multivariate linear
regression. We included gestational age, infant sex, maternal age and parity, and cohort in the
model a priori and then examined the effect of maternal HIV disease severity and treatment
(antenatal CD4 cell count and the use of antiretrovirals) adjusted for the a priori variables. Uni-
variate and multivariate analyses of the association between demographic, feeding and mater-
nal factors affecting longitudinal postnatal growth were examined using mixed effects models
with maximum likelihood estimation. A priori inclusions were similar to the linear regression
model investigating birth weight outcomes. Feeding modality, infant age (continuous variable,
in weeks) and birth weight were additional a priori inclusions. The model was then adjusted
for maternal age, parity, antenatal CD4 count and antiretroviral use. As growth is time depen-
dent, interaction terms with infant age in weeks were included for all covariates. Covariates
(including interaction terms) were included if the p-value was<0.1. As birth weight was a
major determinant of postnatal growth, we conducted a sensitivity analysis limited to children
with normal birth weight to examine the factors associated with growth in this subset of chil-
dren. Owing to the nature of routine clinical data, not all variables were assessed at every visit
or within the time period of this analysis. Cohort was adjusted for in all analyses.
Results
There were 2948 dyads with a minimum of 2 visits, of these 327 (11.1%) were excluded as they
did not have at least one visit after birth within the first 28 weeks of life. The HEU profile of the
dyads included in the analyses is detailed in Fig 1.
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Baseline maternal and infant characteristics
The median age at visits within the first 28 weeks was 2.17 months (IQR 1.48; 2.53 months).
The majority of the infants in this analysis were from RMMCH (Table 1). Overall, 83% of
infants had a normal birth weight (>2 500g) and 51% were male. The overall median birth
WAZ was -0.65 (IQR -1.46; 0.00); lower at RMMCH (-0.68, IQR -1.49; -0.04) compared to MH
(-0.52, IQR -1.23; 0.31). Gestational age at delivery was only available for 70% of infants
(median 39 weeks; IQR 37; 40). Formula feeding was most commonly practised overall
(89.2%), with similarities between sites; 89.1% and 90% of infants at RMMCH and MH were
formula fed respectively. Few infants were mixed fed at MH (0.65%) with no mixed feeding
recorded at RMMCH. Maternal characteristics are detailed in Table 2. The median maternal
age at delivery was similar between the two sites, with most mothers between 25–35 years old.
At MH, where maternal regimen was recorded, 74.8% were on triple therapy (mostly non-
Fig 1. HEU profile.
doi:10.1371/journal.pone.0151762.g001
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nucleo(s)tide reverse transcriptase inhibitors (NNRTI) based), 18.4% on dual therapy, 0.7%
NVP only and 3.6% did not receive antiretrovirals. For most mothers at RMMCH who received
antiretrovirals for PMTCT, the regimen was not recorded (69.9%). A further 15.5% received
Table 1. HEU infant characteristics.
Characteristics McCord Rahima Moosa Overall
n %
missing
median IQR n %
missing
median IQR n median IQR p-value
Infants (n) 310 2311 2621
% male 53.9% 50.6% 51.0% 0.277#
normal (>2500g)
birth weight (n)
279 90% 1892 81.9% 2171 82.8%
anthropometry birth z-scores
birth weight 310 0% -0.52 -1.23;
0.31
2311 0% -0.68 -1.49;
-0.04
2621 -0.65 -1.46;
0.00
0.0005*
Males 167 -0.35 -1.09;
0.31
1169 -0.64 -1.42;
0.04
1336 -0.6 -1.42;
0.065
Females 143 -0.52 -1.47;
0.15
1142 -0.75 -1.56;
-0.08
1285 -0.73 -1.52;
-0.07
birth length 302 2.6% 0.06 -0.62;
1.53
2184 5.50% 0.06 -1.15;
1.12
2486 0.06 -1.0;
1.12
0.0059*
Males 161 0.06 -0.47;
1.12
1109 0.06 -1.0;
1.12
1269 0.06 -1.0;
1.12
Females 141 0.46 -0.62;
1.53
1076 -0.08 -1.15;
0.99
1217 -0.08 -1.15;
0.99
birth head
circumference
301 2.9% 0.42 -0.36;
1.21
2178 5.76% 0.1 -0.74;
0.95
2479 0.1 -0.74;
0.95
0.0001*
Males 162 0.42 -0.36;
1.21
1099 -0.36 -1.15;
1.21
1261 0.42 -1.15;
1.21
Females 139 0.1 -0.74;
0.95
1079 0.1 -0.74;
0.95
1218 0.1 -0.74;
0.95
delivery delivery
variables
gestational age
(weeks)
156 49.7% 38 38; 39 1674 27.56% 39 37; 41 1830 39 37; 40 0.0411*
1 min apgar 288 7.1% 8 7;8 1723 25.44% 9 9;9 2011 9 8;9 <0.0001*
5 min apgar 288 7.1% 9 9;9 1689 26.91% 10 9;10 1977 10 9; 10 <0.0001*
feeding Infant feeding (at birth/1st
visit)
<0.0001#
Exclusive
breastfeeding
10 3.2% 3 0.1% 13 0.5%
Breastfeeding,
exclusivity
unknown
1 0.3% 206 8.9% 207 7.9%
Mixed feeding 2 0.7% - 2 0.1%
Formula feeding 279 90.0% 2059 89.1% 2338 89.2%
Unknown
feeding
18 5.8% 43 1.9% 61 2.3%
visits visits per patient
(n = total obs)
1548 3 2;5 6600 2 1;3 8148 2 1;3 <0.0001*
IQR: inter-quartile range; NVP: nevirapine; AZT: zidovudine; NNRTI: non-nucleot(s)ide reverse transcriptase inhibitors; PI: protease inhibitors
*Wilcoxon rank-sum test
#Chi-squared/Fisher’s exact test
doi:10.1371/journal.pone.0151762.t001
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NVP only, 0.43% triple therapy, 2.9% dual therapy, and 8.5% did not receive antiretrovirals.
For mothers who had antenatal CD4 cell count recorded, 33.6% had a CD4 cell count between
200–500 cells/μl.
Factors affecting birth weight
The models investigating the factors affecting birth weight are found in Tables 3 and 4.
Infants with a gestational age<37 weeks had a lower birth WAZ compared to term infants
Table 2. HEUmaternal characteristics.
Characteristics McCord Rahima Moosa Overall
n median IQR n median IQR n median IQR p-value
Age delivery age (years) 310 29.81 25.63;
33.62
2303 29.57 25.54;
33.56
2613 29.61 25.57;
33.56
0.7995*
age categories 0.473#
missing - - 8 0.4% 8 0.3%
younger mothers 63 20.3% 500 21.6% 563 21.5%
25–35 years 191 61.6% 1369 59.2% 1560 59.5%
older mothers 56 18.1% 434 18.8% 490 18.7%
Parity parity <0.0001#
missing 165 53.2% 126 5.4% 291 11.1%
0 48 15.5% 481 20.8% 529 20.2%
1 62 20.0% 842 36.4% 904 34.5%
2+ 35 11.3% 862 37.3% 897 34.2%
CD4 cells/μl CD4 cells/μl during pregnancy 229 316 207; 471 1330 362 240; 501 1559 357 236; 500 0.0140*
Categorised CD4 cell count <0.0001#‡
missing 81 26.1% 981 42.5% 1062 40.5%
<100 10 3.2% 56 2.4% 66 2.5%
100–200 38 12.3% 176 7.6% 214 8.2%
200–350 81 26.1% 397 17.2% 478 18.2%
350–500 47 15.2% 356 15.4% 403 15.4%
500 53 17.1% 345 14.9% 398 15.2%
Antiretrovirals Antiretroviral (ARV) summary 0.002#§
no drugs 11 3.6% 196 8.5% 207 7.90%
NVP only 2 0.7% 357 15.5% 359 13.7%
AZT only or AZT-NVP
combination
48 15.5% 66 2.9% 114 4.4%
other dual therapy 9 2.9% - 9 0.3%
NNRTI regimen 198 63.9% 10 0.4% 208 7.9%
PI regimen 34 11.0% - 34 1.3%
Received ARVs, regimen
unknown
4 1.3% 1615 69.9% 1619 61.8%
Missing 4 1.3% 67 2.9% 71 2.7%
IQR: inter-quartile range; ARVs: antiretroviral drugs; NVP: nevirapine; AZT: zidovudine; NNRTI: non-nucleot(s)ide reverse transcriptase inhibitors; PI:
protease inhibitors
*Wilcoxon rank-sum test
#Chi-squared/Fisher’s exact test
‡Included all categories of CD4, including missing
§Any ARVs, no ARVs and missing ARVs were compared
doi:10.1371/journal.pone.0151762.t002
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Table 3. Linear regression weight-for-age z-scores including parity andmaternal CD4, birth weight; n = 1397.
unadjusted Adjusted
variables unadjusted ß 95% CI p-value adjusted ß 95% CI p-value
Term  37 weeks 0 0
Premature† -0.865 -1.03; -0.700 * -0.829 -0.995; -0.663 *
Unknown GA -0.056 -0.204; 0.092 0.461 -0.028 -0.176; 0.0120 0.713
Any ARVs 0 0
No ARVs -0.490 -0.781; -0.199 0.001 -0.387 -0.668; -0.106 0.007
ARVs missing information -0.326 -0.876; 0.225 0.246 -0.247 -0.776; 0.281 0.359
25–35 years¶ 0 0
Young mother -0.010 -0.165; 0.144 0.895 0.036 -0.123; 0.194 0.657
Older mother -0.217 -0.378; -0.056 0.008 -0.221 -0.381; -0.061 0.007
Male sex 0 0
Female sex -0.200 -0.321; -0.079 0.001 -0.164 -0.280; -0.049 0.005
CD4 500 0.000 0
CD4 < 200 -0.309 -0.497; -0.122 0.001 -0.253 -0.0434; -0.072 0.006
200 < CD4 < 500 -0.074 -0.217; 0.068 0.305 -0.091 -0.228; 0.045 0.19
parity = 0 0 0
parity = 1 0.212 0.053; 0.372 0.009 0.263 0.105; 0.420 0.001
parity  2 0.084 -0.075; 0.243 0.303 0.211 0.042; 0.381 0.015
GA: gestational age
†Gestational age <37 weeks
¶Maternal age
*p<0.0001
doi:10.1371/journal.pone.0151762.t003
Table 4. Linear regression weight-for-age z-scores, birth weight; n = 2621.
unadjusted adjusted
variables unadjusted ß 95% CI p-value adjusted ß 95% CI p-value
Term  37 weeks 0 0
Premature† -0.926 -1.07; -0.784 * -0.865 -1.007; -0.724 *
Unknown GA -0.405 -0.515; -0.294 * -0.398 -0.510; -0.287 *
Any ARVs 0 0
No ARVs -0.492 -0.678; -0.306 * -0.375 -0.556; -0.194 *
ARVs missing information -0.507 -0.816; -0.198 0.001 -0.376 -0.677; -0.074 0.015
25–35 years¶ 0 0
Young mother -0.025 -0.151; 0.102 0.700 -0.008 -0.130; 0.114 0.902
Older mother -0.299 -0.432; -0.166 * -0.251 -0.379; -0.122 *
Unknown age¶ -0.978 -1.89; -0.065 0.036 -0.592 -1.481; 0.296 0.191
Male sex 0 0
Female sex -0.134 -0.234; -0.033 0.009 -0.110 -0.207; -0.013 0.027
GA: gestational age
†Gestational age <37 weeks
¶Maternal age
*p<0.0001
doi:10.1371/journal.pone.0151762.t004
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(p<0.0001). Females had a lower birth WAZ compared to males (p = 0.005), in agreement
with previous studies [7,12,13,24–26]. When looking at maternal factors, mothers who
received antiretrovirals, irrespective of regimen, delivered infants with a higher birth WAZ.
In comparison to women with a CD4 cell count>500cells/μl, those with lower CD4 cells
counts delivered infants with a lower birth WAZ but this was only significant for mothers with
a CD4<200cells/μl (p = 0.006). Older mothers (>35 years) gave birth to infants with a signifi-
cantly lower birth WAZ compared to mothers 25–35 years old (p = 0.007).
As a sensitivity analysis these factors (except maternal CD4 and parity where there was sub-
stantial missing data) were assessed for the entire HEU cohort, not limited to dyads with com-
plete data on all variables, (Table 4), and they remained consistent, albeit slightly greater in
magnitude.
Effects on growth
The main outcome of this analysis is longitudinal growth of HEU infants. The main model is
presented in Table 5, left side. This model includes parity and thus excludes all dyads missing
information on parity (11.10% overall). The second model, right side of Table 5, shows the
magnitude of effects among all infants, excluding any variables with missing information.
Lastly, in S1 Table, the model including maternal HIV-related variables (CD4 and ARVs) is
shown. Dyads with missing maternal age (0.31% overall), maternal CD4 cell count (40.52%
overall) and parity are excluded. In the reference group of HEU infants (model including par-
ity, Table 3), for male infants of nulliparous women with a birth weight>2 500g born at
RMMCH and who received infant formula, WAZ increased from birth through 28 weeks of
age (adjusted ß 0.019, p-value for interaction<0.0001).
Main model (adjusted analysis, including parity). As expected, infants with a low birth
weight (LBW) had a lower birth WAZ compared to normal birth weight infants, but over time,
growth was significantly faster among LBW infants (adjusted ß 0.07 per week, p-value for
interaction<0.0001). Similarly, infants born to women with parity1 had a higher birth
WAZ but experienced a slower increase in WAZ; although the latter effect was small (adjusted
ß = -0.011) and only statistically significant for infants of mothers with parity2. In this
cohort of HEU infants, females experienced faster growth (adjusted ß 0.014, p-value for inter-
action<0.0001) compared to male infants.
Although BF infants had a marginally greater birth WAZ compared to infants who received
FF (any BF infants p = 0.298), their growth over time was slower compared to infants who
received infant formula (and BF infants adjusted ß – 0.012 p-value for interaction = 0.011,
missing feeding adjusted ß -0.01 p-value for interaction = 0.173). When including all infants,
thus not taking parity into account (Table 3, right side), the effects were similar.
Sensitivity analyses
This same analysis was conducted among infants with a birth weight2 500g (as a sensitivity
analysis) and the direction of these effects remained the same, although the magnitude tended
to be smaller (S2 Table). A model including maternal CD4, antiretrovirals and maternal age
(S1 Table for all infants and S3 Table for normal-weight infants) showed no significant effect
of these on growth over time.
Discussion
In this cohort of HEU infants, mothers with more advanced disease, and those not on antire-
trovirals, delivered infants with a lower birth weight compared to mothers with less advanced
disease, and those who received any antiretrovirals, whether as prophylaxis or triple ART. In
Growth of South African HIV-Exposed Uninfected Infants
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Table 5. Longitudinal linear regression†weight-for-age z-scores 0–28 weeks.
Model including parity; n = 2328 Model including all infants, n = 2621
unadjusted Adjusted unadjusted adjusted
variables unadjusted
ß
95% CI p-
value
adjusted
ß
95% CI p-
value
unadjusted
ß
95% CI p-
value
adjusted
ß
95% CI p-
value
formula feeding 0 0 0 0
any
breastfeeding
0.059 -0.115;
0.232
0.506 0.071 -0.063;
0.206
0.298 0.123 -0.054;
0.300
0.173 0.085 -0.048;
0.218
0.211
breastfeeding x
age
-0.014 -0.024;
-0.005
0.003 -0.012 -0.021;
-0.003
0.011 -0.017 -0.026;
-0.009
* -0.012 -0.020;
-0.003
0.007
unknown feeding -0.062 -0.039;
0.265
0.712 -0.007 -0.260;
0.247
0.958 -0.116 -0.441;
0.210
0.485 -0.016 -0.028;
-0.003
0.017
unknown feeding
x age
-0.006 -0.021;
0.008
0.405 -0.010 -0.024;
0.004
0.173 -0.011 -0.025;
0.002
0.096 -0.028 -0.273;
0.216
0.821
birth weight
2500g
0 0 0 0
birth weight
<2500g
-2.432 -2.539;
-2.326
* -2.432 -2.539;
-2.326
* -2.612 -2.712;
-2.512
* -2.606 -2.707;
-2.506
*
birth weight
<2500g x age
0.068 0.059;
0.076
* 0.070 0.061;
0.078
* 0.067 0.060;
0.074
* 0.068 0.061;
0.076
*
Male sex 0 0 0 0
Female sex (sex) -0.086 -0.185;
0.013
0.088 0.036 -0.041;
0.114
0.357 -0.102 -0.200;
-0.003
0.044 0.057 -0.018;
0.131
0.136
sex x age 0.016 0.010;
0.022
* 0.014 0.008;
0.020
* 0.016 0.010;
0.021
* 0.012 0.007;
0.017
*
RMMCH 0 0 0 0
Cohort 0.261 0.066;
0.456
0.009 0.055 -0.10;
0.205
0.475 0.252 0.104;
0.399
0.001 0.037 -0.074;
0.148
0.514
Cohort x age 0.017 0.009;
0.025
* 0.022 0.014;
0.030
* 0.017 0.011;
0.022
* 0.021 0.015;
0.026
*
age (weeks) 0.032 0.029;
0.036
* 0.019 0.011;
0.027
* 0.036 0.034;
0.039
* 0.015 0.011;
0.020
*
parity = 0 0 0 ‡ ‡
parity = 1 0.159 0.029;
0.290
0.017 0.197 0.092;
0.302
* ‡ ‡
parity = 1 x age -0.002 -0.010;
0.006
0.700 -0.003 -0.011;
0.005
0.488 ‡ ‡
parity  2 0.056 -0.075;
0.186
0.404 0.230 0.115;
0.345
* ‡ ‡
parity  2 x age -0.007 -0.015;
0.001
0.085 -0.011 -0.020;
-0.002
0.015 ‡ ‡
Any ARVs 0 0 0 0
No ARVs -0.383 -0.570;
-0.197
* -0.148 -0.294;
-0.001
0.048 -0.440 -0.624;
-0.257
* -0.164 -0.305;
-0.024
0.022
No ARVs x age 0.001 -0.011;
0.012
0.906 -0.006 -0.017;
0.006
0.332 -0.010 -0.020;
0.001
0.081 -0.014 -0.024;
-0.034
0.009
ARVs missing
information
0.084 -0.251;
0.419
0.623 0.089 -0.172;
0.350
0.505 -0.536 -0.840;
-0.232
0.001 -0.267 -0.499;
-0.036
0.024
ARVs missing
information x age
-0.022 -0.041;
-0.002
0.03 -0.018 -0.037;
0.001
0.067 -0.002 -0.018;
0.014
0.828 -0.006 -0.022;
0.009
0.436
25–35 years¶ 0 0 ‡ ‡
Young mother -0.028 -0.151;
0.096
0.661 0.036 -0.067;
0.140
0.492 ‡ ‡
(Continued)
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contrast, in this cohort of mostly formula fed infants, no maternal HIV disease factors were
associated with postnatal growth, with postnatal WAZ increasing in all children.
Evidence is mixed for the effect of antiretrovirals on birth weight and preterm deliveries,
although triple ART, especially the use of protease inhibitor-containing (PI) regimens, either
pre-conception or initiated during pregnancy appears to increase the risk of both LBW and
preterm deliveries [27,28].The PROMISE trial found no significant differences between three
regimens for both very preterm (<34 weeks) and very low birth weight (<1500g) [29]. We
found antiretroviral use protective against LBW. In our study, relatively few women would
have conceived on ART and very few were on PI-containing regimens. Maternal triple ART
would have been restricted to mothers with advanced disease. In addition, all types of antiretro-
viral exposure were combined in this analysis so the effects seen are probably due to the partial
mitigation of the effects of severe maternal disease by antiretrovirals.
Most HEU infants in the IeDEA-SA collaboration were formula fed—the predominant
feeding modality at both sites. MBF infants experienced marginally slower growth compared to
FF infants. Although MBF infants experienced slower growth, the effect was very small and it is
difficult to draw robust conclusions particularly as less than 10% of infants in this HEU cohort
received any breast milk. Furthermore, we did not have detailed data on confounding factors
that could impact growth and feeding choice, such as maternal education [4,8,16,17] and socio-
economic status [4,16,17]. Goga et al [14] found differences between sites for the combined
end-point of HIV transmission or death, and Ramokolo et al found differences in growth
across the same sites [30], thus the effect of different settings and patient characteristics within
these settings are an important consideration. It is important to note the reality that most
infants were not exclusively breastfed and many were FF. While this may have changed
recently with the introduction of option B/B+ in South Africa, strategies to support breastfeed-
ing and optimise growth outcomes in the context of actual infant feeding choices need to be
developed and encouraged.
Advanced maternal disease has been shown to negatively impact on growth [4,16], although
in this analysis, maternal CD4 and the use of antiretrovirals did not have a significant impact
on growth. This may be because maternal antiretroviral use and CD4 data were limited to the
antenatal period and may not reflect the maternal disease status after delivery. In addition, the
availability of triple therapy for all women with a CD4 cell count<350 cells/μl after 2010 may
Table 5. (Continued)
Model including parity; n = 2328 Model including all infants, n = 2621
unadjusted Adjusted unadjusted adjusted
variables unadjusted
ß
95% CI p-
value
adjusted
ß
95% CI p-
value
unadjusted
ß
95% CI p-
value
adjusted
ß
95% CI p-
value
Young mother x
age
-0.0002 -0.008;
0.007
0.959 -0.003 -0.011;
0.005
0.448 ‡ ‡
Older mother -0.288 -0.419;
-0.158
* -0.119 -0.225;
-0.012
0.028 ‡ ‡
Older mother x
age
0.006 -0.002;
0.014
0.171 0.004 -0.004;
0.012
0.364 ‡ ‡
¶Maternal age
‡Not included in the model
*p<0.0001
†Reference categories: Feeding–any breastfeeding, Birth weight - 2500g, Sex–males, Cohort–McCord, parity– 0 children
doi:10.1371/journal.pone.0151762.t005
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have mitigated the adverse effects of severe maternal disease seen in studies prior to such anti-
retroviral availability.
In this analysis, female infants experienced faster growth compared to male infants. Inter-
estingly, previous studies examining growth among HEU infants have mostly not examined
the effect of infant sex [5,8,16]. However, Kuhn et al found that female infants had lower actual
weight compared to male infants between 1 week and 4 months of age [4], while in a Ugandan
study female infants had lower odds of experiencing stunting (length-for-age z-score<-2) or
being underweight (WAZ<-2) compared to male infants [17].
Strengths and limitations
The major strength of this study is the large number of mother-infant dyads included and the
description of feeding practices and growth in infants in a routine care setting. Most previous
studies of growth in HEU infants in South Africa have been restricted to research cohorts and
randomised controlled trial data, where results may differ compared to infants in routine care.
However, the reliance on routinely collected data meant that a number of key variables were
missing. For example, although only 5% of birth length and head circumference were missing,
these were not regularly measured and recorded at follow-up visits so we were unable to exam-
ine length-for-age and weight-for-length z-scores over time. Furthermore, although standard
practice was employed for growth monitoring, no quality assurance processes were in place.
Information on antiretrovirals given to infants themselves for PMTCT was inadequate thus we
were unable to take it into account. Similarly, the introduction of solids was not routinely
assessed and could not be included in the multivariate analyses. A previous study evaluating
infant feeding practices found that 47% of HIV-infected mothers did not initiate breastfeeding;
however, 67% of these mothers who initiated FF were practising mixed formula feeding by 3
weeks of age [14]. Mixed FF also comprises mixed feeding; as the introduction of solids was
not assessed the extent of mixed FF in this cohort of HEU infants is unknown. Feeding modal-
ity and maternal disease severity are known to influence risk of infection in infants [4,10]
which would affect growth. However as opportunistic infections were not routinely recorded at
sites, this was not investigated.
As only antenatal maternal disease-related factors were included in this analysis, it could
account for our finding of an impact on birth WAZ, but not longitudinal WAZ. The impact of
postnatal maternal disease severity may have an impact on infant growth outcomes, particu-
larly if infants are breastfed, as it’s been shown that mothers who have more advanced disease
have poorer infant outcomes [4,5,8,15–17,31–33], not merely limited to growth
In our cohort of HEU infants birth WAZ was low overall, but whether this was as a result of
HIV-exposure or not is unknown. A comparison between HEU infants and unexposed unin-
fected infants is needed to investigate this further. Two South African studies have found that
HEU infants have similar growth outcomes compared to unexposed infants, with one study
only finding differences between the ages of 25–39 weeks [5,30].
Conclusion
Despite the limitations imposed by routine clinical data, this analysis shows that maternal anti-
retrovirals and less severe maternal disease have a positive impact on birth weight. We also
found that any breastfeeding was rare in this cohort with MBF infants experiencing only mar-
ginally slower growth compared to FF infants. With the introduction of option B/B+ it will be
important to examine the impact on infant feeding pattern, infant morbidity and the impact
on growth in the growing population of HEU infants.
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